Skip to content

Biohaven BHVN Common Stock, Shares, Outstanding

Common Stock, Shares, Outstanding at other companies

Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
Roivant Sciences logo
Roivant SciencesROIV
BridgeBio Pharma logo
BridgeBio PharmaBBIO
ADMA Biologics logo
ADMA BiologicsADMA
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesOutstanding.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's common stock, shares, outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's common stock, shares, outstanding?
Biohaven (BHVN) reported common stock, shares, outstanding of $150.51M in Q1 2026.
How has Biohaven's common stock, shares, outstanding changed year-over-year?
Biohaven's common stock, shares, outstanding increased by 47.4% year-over-year, from $102.1M to $150.51M.
What is the long-term trend for Biohaven's common stock, shares, outstanding?
Over 3 years (2022 to 2025), Biohaven's common stock, shares, outstanding has grown at a 24.9% compound annual growth rate (CAGR), from $68.19M to $132.78M.